Follow us as we translate our deep expertise in structure-based drug discovery into novel, selective therapeutics that enable durable responses for patients with cancer.

Patient Impact Drives Solutions
James R. Porter, Ph. D.
James R. Porter, PhD
Chief Executive Officer
Jim shares more about Nuvalent’s foundation and approach – to provide new impactful therapies for patients living with cancer.

You are about to leave the Nuvalent website.

Nuvalent does not endorse or take responsibility for any information or statements made on external sites.

Do you wish to continue?